NCT04600934

Brief Summary

Annually, 150-200 TAVR with unilateral large bore access and 200 combined TEVAR/EVAR/FEVAR with bilateral large bore access are performed at our institution. Nearly 50 percent of patients fall outside IFU for access vessel size. Adjuncts described include iliac conduit, crack and pave, balloon expandable sheaths, direct aortic puncture, transcaval delivery, alternative access point (i.e axillary, carotid). Each of these adjuncts comes with additional complication potential and by nature of being used less frequently than the standard femoral access makes the procedure more challenging. The intervention the use of the Shockwave Medical, Inc. Peripheral Lithoplasty® System to achieve large bore access in patients whose vessels fall outside of the IFU suggested dimensions.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2022

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 19, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 23, 2020

Completed
1.9 years until next milestone

Study Start

First participant enrolled

October 3, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 28, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 28, 2023

Completed
Last Updated

September 3, 2024

Status Verified

September 1, 2023

Enrollment Period

12 months

First QC Date

October 19, 2020

Last Update Submit

August 29, 2024

Conditions

Keywords

Vascular Surgery

Outcome Measures

Primary Outcomes (1)

  • Successful advancement of planned large bore access device

    Technical success-defined as successful advancement of planned large bore access device without use of additional adjuncts (stenting, repeat shockwave treatment, high pressure balloon, alternative access pathway)

    Day 1

Study Arms (2)

Standard POBA (plain old balloon angioplasty)

ACTIVE COMPARATOR

The first 50 patients will be pre-treated with standard POBA

Device: Plain old balloon angioplasty

Shockwave

EXPERIMENTAL

The second 50 patients will be treated primarily with Shockwave

Device: Shockwave

Interventions

ShockwaveDEVICE

Shockwave Medical, Inc. Peripheral Lithoplasty® System

Shockwave

POBA

Standard POBA (plain old balloon angioplasty)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>18 years
  • Indicated for planned procedure requiring large bore (\>12 French sheath) access
  • Mental capacity to provide informed consent
  • Iliac access vessel demonstrates \>50% circumferential calcium
  • Iliac access vessel demonstrates maximum inner lumen diameter less than IFU for device required
  • Iliac access vessel demonstrates maximum outer wall diameter greater than or equal to IFU for device required
  • Preoperative CT angiogram, \</= 5mm slices
  • Preoperative ABI/TP
  • Unsuccessful delivery of large bore sheath without adjunctive intervention
  • o Definition of unsuccessful = operator assessment of the following
  • Visible distortion of iliac artery calcification under fluoroscopy without forward progress of device
  • Adverse forward pressure application by operator
  • Failure of device to track with external pressure applied to abdomen
  • Patient intolerance of advancement (pain response) in awake patient

You may not qualify if:

  • Contraindicated for antiplatelet therapy (aspirin or plavix)
  • Planned iliofemoral surgical reconstruction in next 30 days
  • Prior common or external iliac artery stent placement
  • Prior aorto-iliac, aorto-femoral, or iliofemoral bypass present
  • Iliac access vessel demonstrates maximum outer wall diameter less than IFU for device required
  • Inability to obtain preoperative CTA (contrast allergy, CKD, etc)
  • Inability to traverse iliac segment with wire
  • Emergent procedure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

MeSH Terms

Conditions

Vascular Diseases

Condition Hierarchy (Ancestors)

Cardiovascular Diseases

Study Officials

  • Mathew Wooster, MD

    Medical University of South Carolina

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

October 19, 2020

First Posted

October 23, 2020

Study Start

October 3, 2022

Primary Completion

September 28, 2023

Study Completion

September 28, 2023

Last Updated

September 3, 2024

Record last verified: 2023-09

Locations